Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma

BACKGROUND: Programmed cell death 1 (PD1) inhibitors have recently shown promising anti-cancer effects in a number of solid tumor types. A predictive biomarker to this class of drugs has not been clearly identified; however, overexpression of the PD1 ligand (PD-L1) has shown particular promise in lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessier-Cloutier, Basile, Kalloger, Steve E., Al-Kandari, Mohammad, Milne, Katy, Gao, Dongxia, Nelson, Brad H., Renouf, Daniel J., Sheffield, Brandon S., Schaeffer, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584324/
https://www.ncbi.nlm.nih.gov/pubmed/28870260
http://dx.doi.org/10.1186/s12885-017-3634-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584324/
https://www.ncbi.nlm.nih.gov/pubmed/28870260
http://dx.doi.org/10.1186/s12885-017-3634-5

Ejemplares similares